Arrivent BioPharma, Inc. (AVBP)
29.79
-0.49
(-1.62%)
USD |
NASDAQ |
Sep 09, 16:00
29.84
+0.06
(+0.18%)
After-Hours: 20:00
Arrivent BioPharma Enterprise Value : 1.067B for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 1.067B |
| September 08, 2026 | 1.090B |
| September 04, 2026 | 1.123B |
| September 03, 2026 | 1.127B |
| September 02, 2026 | 1.101B |
| September 01, 2026 | 1.084B |
| August 31, 2026 | 1.079B |
| August 28, 2026 | 1.085B |
| August 27, 2026 | 1.125B |
| August 26, 2026 | 1.132B |
| August 25, 2026 | 1.142B |
| August 24, 2026 | 992.74M |
| August 21, 2026 | 1.034B |
| August 20, 2026 | 1.037B |
| August 19, 2026 | 1.078B |
| August 18, 2026 | 1.077B |
| August 17, 2026 | 1.029B |
| August 14, 2026 | 1.053B |
| August 13, 2026 | 1.077B |
| August 12, 2026 | 1.147B |
| August 11, 2026 | 1.144B |
| August 10, 2026 | 1.125B |
| August 07, 2026 | 1.117B |
| August 06, 2026 | 1.126B |
| August 05, 2026 | 1.106B |
| Date | Value |
|---|---|
| August 04, 2026 | 1.149B |
| August 03, 2026 | 1.059B |
| July 31, 2026 | 1.068B |
| July 30, 2026 | 1.109B |
| July 29, 2026 | 1.079B |
| July 28, 2026 | 1.076B |
| July 27, 2026 | 1.085B |
| July 24, 2026 | 1.160B |
| July 23, 2026 | 1.151B |
| July 22, 2026 | 1.098B |
| July 21, 2026 | 992.74M |
| July 20, 2026 | 990.81M |
| July 17, 2026 | 1.231B |
| July 16, 2026 | 1.210B |
| July 15, 2026 | 1.219B |
| July 14, 2026 | 1.200B |
| July 13, 2026 | 1.253B |
| July 10, 2026 | 1.255B |
| July 09, 2026 | 1.254B |
| July 08, 2026 | 1.241B |
| July 07, 2026 | 1.279B |
| July 06, 2026 | 1.294B |
| July 02, 2026 | 1.302B |
| July 01, 2026 | 1.294B |
| June 30, 2026 | 1.306B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cytokinetics, Inc. | 10.39B |
| Gilead Sciences, Inc. | 202.03B |
| Ionis Pharmaceuticals, Inc. | 9.413B |
| Vertex Pharmaceuticals, Inc. | 126.14B |
| ACADIA Pharmaceuticals, Inc. | 3.882B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.89M |
| Total Expenses (Quarterly) | 49.89M |
| EPS Diluted (Quarterly) | -1.048 |
| Earnings Yield | -12.36% |
| Normalized Earnings Yield | -12.36 |